240 related articles for article (PubMed ID: 28292898)
1. Multisite aggregation of p53 and implications for drug rescue.
Wang G; Fersht AR
Proc Natl Acad Sci U S A; 2017 Mar; 114(13):E2634-E2643. PubMed ID: 28292898
[TBL] [Abstract][Full Text] [Related]
2. Amyloidogenicity of p53: a hidden link between protein misfolding and cancer.
Gong H; Yang X; Zhao Y; Petersen RB; Liu X; Liu Y; Huang K
Curr Protein Pept Sci; 2015; 16(2):135-46. PubMed ID: 25692950
[TBL] [Abstract][Full Text] [Related]
3. Targeting the Prion-like Aggregation of Mutant p53 to Combat Cancer.
Silva JL; Cino EA; Soares IN; Ferreira VF; A P de Oliveira G
Acc Chem Res; 2018 Jan; 51(1):181-190. PubMed ID: 29260852
[TBL] [Abstract][Full Text] [Related]
4. Propagation of aggregated p53: Cross-reaction and coaggregation vs. seeding.
Wang G; Fersht AR
Proc Natl Acad Sci U S A; 2015 Feb; 112(8):2443-8. PubMed ID: 25675527
[TBL] [Abstract][Full Text] [Related]
5. The Lys-Specific Molecular Tweezer, CLR01, Modulates Aggregation of the Mutant p53 DNA Binding Domain and Inhibits Its Toxicity.
Herzog G; Shmueli MD; Levy L; Engel L; Gazit E; Klärner FG; Schrader T; Bitan G; Segal D
Biochemistry; 2015 Jun; 54(24):3729-38. PubMed ID: 26030124
[TBL] [Abstract][Full Text] [Related]
6. Protein mimetic amyloid inhibitor potently abrogates cancer-associated mutant p53 aggregation and restores tumor suppressor function.
Palanikumar L; Karpauskaite L; Al-Sayegh M; Chehade I; Alam M; Hassan S; Maity D; Ali L; Kalmouni M; Hunashal Y; Ahmed J; Houhou T; Karapetyan S; Falls Z; Samudrala R; Pasricha R; Esposito G; Afzal AJ; Hamilton AD; Kumar S; Magzoub M
Nat Commun; 2021 Jun; 12(1):3962. PubMed ID: 34172723
[TBL] [Abstract][Full Text] [Related]
7. Investigating the intrinsic aggregation potential of evolutionarily conserved segments in p53.
Ghosh S; Ghosh D; Ranganathan S; Anoop A; P SK; Jha NN; Padinhateeri R; Maji SK
Biochemistry; 2014 Sep; 53(38):5995-6010. PubMed ID: 25181279
[TBL] [Abstract][Full Text] [Related]
8. Mutant p53 aggregates into prion-like amyloid oligomers and fibrils: implications for cancer.
Ano Bom AP; Rangel LP; Costa DC; de Oliveira GA; Sanches D; Braga CA; Gava LM; Ramos CH; Cepeda AO; Stumbo AC; De Moura Gallo CV; Cordeiro Y; Silva JL
J Biol Chem; 2012 Aug; 287(33):28152-62. PubMed ID: 22715097
[TBL] [Abstract][Full Text] [Related]
9. Polyarginine and its analogues inhibit p53 mutant aggregation and cancer cell proliferation in vitro.
Chen Z; Chen J; Keshamouni VG; Kanapathipillai M
Biochem Biophys Res Commun; 2017 Jul; 489(2):130-134. PubMed ID: 28536076
[TBL] [Abstract][Full Text] [Related]
10. Aggregation-primed molten globule conformers of the p53 core domain provide potential tools for studying p53C aggregation in cancer.
Pedrote MM; de Oliveira GAP; Felix AL; Mota MF; Marques MA; Soares IN; Iqbal A; Norberto DR; Gomes AMO; Gratton E; Cino EA; Silva JL
J Biol Chem; 2018 Jul; 293(29):11374-11387. PubMed ID: 29853637
[TBL] [Abstract][Full Text] [Related]
11. Effect of Mutation on an Aggregation-Prone Segment of p53: From Monomer to Dimer to Multimer.
Das A; Makarov DE
J Phys Chem B; 2016 Nov; 120(45):11665-11673. PubMed ID: 27775362
[TBL] [Abstract][Full Text] [Related]
12. Molecular dynamics study on the inhibition mechanisms of ReACp53 peptide for p53-R175H mutant aggregation.
Lei J; Cai M; Shen Y; Lin D; Deng X
Phys Chem Chem Phys; 2021 Oct; 23(40):23032-23041. PubMed ID: 34612239
[TBL] [Abstract][Full Text] [Related]
13. Methods to Screen Compounds Against Mutant p53 Misfolding and Aggregation for Cancer Therapeutics.
Ferretti GDDS; da Costa DCF; L Silva J; Pereira Rangel L
Methods Mol Biol; 2019; 1873():265-277. PubMed ID: 30341616
[TBL] [Abstract][Full Text] [Related]
14. Kinetic mechanism of p53 oncogenic mutant aggregation and its inhibition.
Wilcken R; Wang G; Boeckler FM; Fersht AR
Proc Natl Acad Sci U S A; 2012 Aug; 109(34):13584-9. PubMed ID: 22869713
[TBL] [Abstract][Full Text] [Related]
15. Gain of function of mutant p53 by coaggregation with multiple tumor suppressors.
Xu J; Reumers J; Couceiro JR; De Smet F; Gallardo R; Rudyak S; Cornelis A; Rozenski J; Zwolinska A; Marine JC; Lambrechts D; Suh YA; Rousseau F; Schymkowitz J
Nat Chem Biol; 2011 May; 7(5):285-95. PubMed ID: 21445056
[TBL] [Abstract][Full Text] [Related]
16. Characterization of full-length p53 aggregates and their kinetics of formation.
Julian L; Sang JC; Wu Y; Meisl G; Brelstaff JH; Miller A; Cheetham MR; Vendruscolo M; Knowles TPJ; Ruggeri FS; Bryant C; Ros S; Brindle KM; Klenerman D
Biophys J; 2022 Nov; 121(22):4280-4298. PubMed ID: 36230002
[TBL] [Abstract][Full Text] [Related]
17. Aggregation tendencies in the p53 family are modulated by backbone hydrogen bonds.
Cino EA; Soares IN; Pedrote MM; de Oliveira GA; Silva JL
Sci Rep; 2016 Sep; 6():32535. PubMed ID: 27600721
[TBL] [Abstract][Full Text] [Related]
18. Common cancer mutations R175H and R273H drive the p53 DNA-binding domain towards aggregation-prone conformations.
Li L; Li X; Tang Y; Lao Z; Lei J; Wei G
Phys Chem Chem Phys; 2020 May; 22(17):9225-9232. PubMed ID: 32307496
[TBL] [Abstract][Full Text] [Related]
19. p53 reactivation with induction of massive apoptosis-1 (PRIMA-1) inhibits amyloid aggregation of mutant p53 in cancer cells.
Rangel LP; Ferretti GDS; Costa CL; Andrade SMMV; Carvalho RS; Costa DCF; Silva JL
J Biol Chem; 2019 Mar; 294(10):3670-3682. PubMed ID: 30602570
[TBL] [Abstract][Full Text] [Related]
20. The aggregation of mutant p53 produces prion-like properties in cancer.
Rangel LP; Costa DC; Vieira TC; Silva JL
Prion; 2014; 8(1):75-84. PubMed ID: 24509441
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
